- Home
- INFA vs ROIV Comparison
INFA vs ROIV Comparison
Compare INFA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFA
- ROIV
- Stock Information
- Founded
- INFA 1993
- ROIV 2014
- Country
- INFA United States
- ROIV United Kingdom
- Employees
- INFA N/A
- ROIV N/A
- Industry
- INFA EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- INFA Technology
- ROIV Health Care
- Exchange
- INFA Nasdaq
- ROIV Nasdaq
- Market Cap
- INFA 8.1B
- ROIV 8.4B
- IPO Year
- INFA 2021
- ROIV N/A
- Fundamental
- Price
- INFA $26.76
- ROIV $11.82
- Analyst Decision
- INFA Buy
- ROIV Strong Buy
- Analyst Count
- INFA 13
- ROIV 10
- Target Price
- INFA $32.15
- ROIV $17.39
- AVG Volume (30 Days)
- INFA 1.3M
- ROIV 4.0M
- Earning Date
- INFA 10-30-2024
- ROIV 11-11-2024
- Dividend Yield
- INFA N/A
- ROIV N/A
- EPS Growth
- INFA N/A
- ROIV N/A
- EPS
- INFA 0.53
- ROIV 5.65
- Revenue
- INFA $1,642,973,000.00
- ROIV $158,303,000.00
- Revenue This Year
- INFA $6.82
- ROIV $53.59
- Revenue Next Year
- INFA $7.04
- ROIV $26.91
- P/E Ratio
- INFA $50.48
- ROIV $2.05
- Revenue Growth
- INFA 8.65
- ROIV 101.44
- 52 Week Low
- INFA $18.71
- ROIV $8.29
- 52 Week High
- INFA $39.80
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- INFA 61.88
- ROIV 47.60
- Support Level
- INFA $26.26
- ROIV $11.52
- Resistance Level
- INFA $27.23
- ROIV $12.08
- Average True Range (ATR)
- INFA 0.53
- ROIV 0.22
- MACD
- INFA -0.01
- ROIV -0.01
- Stochastic Oscillator
- INFA 76.03
- ROIV 29.40
About INFA Informatica Inc.
Informatica Inc is a pioneered new category of software, the Intelligent Data Management Cloud, or IDMC. IDMC is an AI-powered platform that connects, manages, and unifies data across any multi-cloud, hybrid system, empowering enterprises to modernize and advance data strategies.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.